SCHEMBL253380

SCHEMBL253380

CCOC(=O)c1cc(-c2ccccc2)n(Cc2ccccc2F)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 2/20 0.51
SLC16A1 P53985 2/20 0.51
MCTS1 Q9ULC4 2/20 0.51
CA9 Q16790 1/20 0.50
FAAH O00519 2/20 0.49
NR1H2 P55055 2/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CACNA1G O43497 1/20 0.47
CACNA1H O95180 1/20 0.47
ALDH1A1 P00352 2/20 0.47
P2RY14 Q15391 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CHRNA7 P36544 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10324711 0.87 SLC16A3 (0.47) SLC16A3SLC16A1MCTS1CA9FAAH
SCHEMBL17611623 0.86 TP53 (0.50) TP53POLBSMN1; SMN2ALDH1A1P2RY14
SCHEMBL15964665 0.86 CYP1A2 (0.54) TP53POLBSMN1; SMN2ALDH1A1P2RY14
SCHEMBL29831851 0.86 CYP1A2 (0.54) TP53POLBSMN1; SMN2ALDH1A1P2RY14
SCHEMBL2227637 0.86 SMN1; SMN2 (0.64) SLC16A3CA9FAAHNR1H2POLB
SCHEMBL17610985 0.85 P2RY14 (0.50) TP53POLBSMN1; SMN2ALDH1A1P2RY14
SCHEMBL253135 0.85 ALDH1A1 (0.44) SLC16A3SLC16A1MCTS1FAAHTP53
SCHEMBL30121985 0.85 TP53 (0.48) TP53POLBSMN1; SMN2ALDH1A1P2RY14
SCHEMBL15075362 0.85 TP53 (0.48) TP53POLBSMN1; SMN2ALDH1A1P2RY14
SCHEMBL2921176 0.85 SMN1; SMN2 (0.52) TP53POLBSMN1; SMN2ALDH1A1P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243177-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2025-07-31 US disclosed
CN-107021951-B sGC stimulators 赛克里翁治疗有限公司 2020-10-20 CN disclosed
US-20190345130-A1 SGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2019-11-14 US disclosed
US-20190345130-A1 SGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2019-11-14 US disclosed
US-10189809-B2 SGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2019-01-29 US disclosed
US-10189809-B2 SGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2019-01-29 US disclosed
US-20170305878-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-10-26 US disclosed
US-20170305878-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-10-26 US disclosed
US-20170305878-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-10-26 US disclosed
EP-3173407-A1 SGC STIMULATORS Ironwood Pharmaceuticals, Inc. (US) 2017-05-31 EP disclosed
US-20140323448-A1 sGC STIMULATORS Ironwood Pharmaceuticals Inc. (US) 2014-10-30 US disclosed
US-8748442-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2014-06-10 US disclosed
US-8748442-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2014-06-10 US disclosed
US-8748442-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2014-06-10 US disclosed
EP-2588465-A1 SGC STIMULATORS Ironwood Pharmaceuticals, Inc. (US) 2013-05-08 EP disclosed
US-20120184516-A1 sGC Stimulators CYCLERION THERAPEUTICS, INC. 2012-07-19 US disclosed
US-20120184516-A1 sGC Stimulators CYCLERION THERAPEUTICS, INC. 2012-07-19 US disclosed
US-20120184516-A1 sGC Stimulators CYCLERION THERAPEUTICS, INC. 2012-07-19 US disclosed
WO-2012003405-A1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-01-05 WO disclosed
WO-2012003405-A1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323448-A1 sGC STIMULATORS GUCY1A1, PTGIS, GUCY1B1 SLC16A3 4528/4885SLC16A1 4078/4885MCTS1 2156/4885
US-20120184516-A1 sGC Stimulators GUCY1A1, PTGIS, GUCY1B1 SLC16A3 4528/4885SLC16A1 4078/4885MCTS1 2156/4885
US-20170305878-A1 sGC STIMULATORS GUCY1A1, PTGIS, GUCY1B1 SLC16A3 4528/4885SLC16A1 4078/4885MCTS1 2156/4885
US-10189809-B2 SGC stimulators GUCY1A1, PTGIS, GUCY1B1 SLC16A3 4528/4885SLC16A1 4078/4885MCTS1 2156/4885
US-20190345130-A1 SGC STIMULATORS GUCY1A1, PTGIS, GUCY1B1 SLC16A3 4528/4885SLC16A1 4078/4885MCTS1 2156/4885
US-20250243177-A1 sGC STIMULATORS GUCY1A1, PTGIS, GUCY1B1 SLC16A3 4528/4885SLC16A1 4078/4885MCTS1 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.